Literature DB >> 22836088

AXL and acquired resistance to EGFR inhibitors.

Sophie Postel-Vinay, Alan Ashworth.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22836088     DOI： 10.1038/ng.2362

Source DB:  PubMed          Journal:  Nat Genet        ISSN： 1061-4036            Impact factor:   38.330


× No keyword cloud information.
  12 in total

Review 1.  Targeting Axl and Mer kinases in cancer.

Authors:  Anupam Verma; Steven L Warner; Hariprasad Vankayalapati; David J Bearss; Sunil Sharma
Journal:  Mol Cancer Ther       Date:  2011-09-20       Impact factor: 6.261

Review 2.  Comparing antibody and small-molecule therapies for cancer.

Authors:  Kohzoh Imai; Akinori Takaoka
Journal:  Nat Rev Cancer       Date:  2006-09       Impact factor: 60.716

3.  Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.

Authors:  Jamie E Chaft; Geoffrey R Oxnard; Camelia S Sima; Mark G Kris; Vincent A Miller; Gregory J Riely
Journal:  Clin Cancer Res       Date:  2011-08-19       Impact factor: 12.531

4.  Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.

Authors:  Geoffrey R Oxnard; Maria E Arcila; Camelia S Sima; Gregory J Riely; Juliann Chmielecki; Mark G Kris; William Pao; Marc Ladanyi; Vincent A Miller
Journal:  Clin Cancer Res       Date:  2010-12-06       Impact factor: 12.531

Review 5.  Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors.

Authors:  Rachel M A Linger; Amy K Keating; H Shelton Earp; Douglas K Graham
Journal:  Expert Opin Ther Targets       Date:  2010-10       Impact factor: 6.902

6.  Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.

Authors:  Lecia V Sequist; Belinda A Waltman; Dora Dias-Santagata; Subba Digumarthy; Alexa B Turke; Panos Fidias; Kristin Bergethon; Alice T Shaw; Scott Gettinger; Arjola K Cosper; Sara Akhavanfard; Rebecca S Heist; Jennifer Temel; James G Christensen; John C Wain; Thomas J Lynch; Kathy Vernovsky; Eugene J Mark; Michael Lanuti; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Sci Transl Med       Date:  2011-03-23       Impact factor: 17.956

7.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

Authors:  William Pao; Vincent Miller; Maureen Zakowski; Jennifer Doherty; Katerina Politi; Inderpal Sarkaria; Bhuvanesh Singh; Robert Heelan; Valerie Rusch; Lucinda Fulton; Elaine Mardis; Doris Kupfer; Richard Wilson; Mark Kris; Harold Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-25       Impact factor: 11.205

8.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

9.  Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

Authors:  David Jackman; William Pao; Gregory J Riely; Jeffrey A Engelman; Mark G Kris; Pasi A Jänne; Thomas Lynch; Bruce E Johnson; Vincent A Miller
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

10.  Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.

Authors:  Zhenfeng Zhang; Jae Cheol Lee; Luping Lin; Victor Olivas; Valerie Au; Thomas LaFramboise; Mohamed Abdel-Rahman; Xiaoqi Wang; Alan D Levine; Jin Kyung Rho; Yun Jung Choi; Chang-Min Choi; Sang-We Kim; Se Jin Jang; Young Soo Park; Woo Sung Kim; Dae Ho Lee; Jung-Shin Lee; Vincent A Miller; Maria Arcila; Marc Ladanyi; Philicia Moonsamy; Charles Sawyers; Titus J Boggon; Patrick C Ma; Carlota Costa; Miquel Taron; Rafael Rosell; Balazs Halmos; Trever G Bivona
Journal:  Nat Genet       Date:  2012-07-01       Impact factor: 38.330
View more
  18 in total

1.  EGFR: The Paradigm of an Oncogene-Driven Lung Cancer.

Authors:  Gregory J Riely; Helena A Yu
Journal:  Clin Cancer Res       Date:  2015-05-15       Impact factor: 12.531

Review 2.  Kinase inhibitors: the road ahead.

Authors:  Fleur M Ferguson; Nathanael S Gray
Journal:  Nat Rev Drug Discov       Date:  2018-03-16       Impact factor: 84.694

3.  ABL regulation by AXL promotes cisplatin resistance in esophageal cancer.

Authors:  Jun Hong; Dunfa Peng; Zheng Chen; Vikas Sehdev; Abbes Belkhiri
Journal:  Cancer Res       Date:  2012-11-01       Impact factor: 12.701

4.  HGF-induced formation of the MET-AXL-ELMO2-DOCK180 complex promotes RAC1 activation, receptor clustering, and cancer cell migration and invasion.

Authors:  Wenjing Li; Xiahui Xiong; Amro Abdalla; Salvador Alejo; Linyu Zhu; Fei Lu; Hong Sun
Journal:  J Biol Chem       Date:  2018-08-14       Impact factor: 5.157

5.  Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.

Authors:  Nitu Bansal; Prasun J Mishra; Mark Stein; Robert S DiPaola; Joseph R Bertino
Journal:  Oncotarget       Date:  2015-06-20

6.  Heterozygous mutations in AAGAB cause type 1 punctate palmoplantar keratoderma with evidence for increased growth factor signaling.

Authors:  Elizabeth Pöhler; Mozheh Zamiri; Catriona P Harkins; Julio C Salas-Alanis; William Perkins; Frances J D Smith; W H Irwin McLean; Sara J Brown
Journal:  J Invest Dermatol       Date:  2013-06-06       Impact factor: 8.551

7.  Reversal of Cisplatin resistance by epigallocatechin gallate is mediated by downregulation of axl and tyro 3 expression in human lung cancer cells.

Authors:  Kyung-Chan Kim; Chuhee Lee
Journal:  Korean J Physiol Pharmacol       Date:  2014-02-13       Impact factor: 2.016

8.  AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells.

Authors:  Yun Jung Choi; Seon Ye Kim; Kwang Sup So; In-Jeoung Baek; Woo Sung Kim; Se Hoon Choi; Jae Cheol Lee; Trever G Bivona; Jin Kyung Rho; Chang-Min Choi
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

Review 9.  Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance.

Authors:  D Gonzalez de Castro; P A Clarke; B Al-Lazikani; P Workman
Journal:  Clin Pharmacol Ther       Date:  2012-12-07       Impact factor: 6.875

10.  Design, synthesis, and validation of Axl-targeted monoclonal antibody probe for microPET imaging in human lung cancer xenograft.

Authors:  Shuanglong Liu; Dan Li; Jiacong Guo; Nicolette Canale; Xiuqing Li; Ren Liu; Valery Krasnoperov; Parkash S Gill; Peter S Conti; Hong Shan; Zibo Li
Journal:  Mol Pharm       Date:  2014-07-09       Impact factor: 4.939
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.